July 3, 2023 - dsm-firmenich, innovators in nutrition, health, and beauty, confirms the completion of its acquisition of Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.
Postbiotics is a rapidly emerging segment of the health through the gut market, offering longer shelf-life and greater application versatility than probiotics while providing sustained health benefits. With the benefits of their use supported by a growing boy of robust scientific evidence, they represent the next wave of opportunity in the gut health market.
Philip Eykerman, dsm-firmenich's President Health, Nutrition & Care, said: "Adare Biome, as a global leader in the research and manufacturing of postbiotics with over a century of pioneering science in its heritage, is a perfect fit for dsm-firmenich that will complement three of our four Business Units. The Adare Biome teams bring great knowledge in this area which will greatly help in driving our 'Health from the Gut' strategy and enable us to accelerate the creation of next-generation bionics to support the health of people and animals. We are excited about the new opportunities this move will unlock, as dsm-firmenich's strong global presence and reach in local markets will enable us to deliver Adare Biome products to customers in a faster, more efficient way to bring the proven benefits of postbiotics to a wider range of people around the world. We welcome the Adare Biome team members to the dsm-firmenich family."
dsm-firmenich intends to extend the availability of Adare Biome's over the counter post biotic supplement for relieving gut upsets Lactéol® through its B2C unit, i-Health. Further development of post biotic B2B ingredients will include opportunities in dietary supplements, early life nutrition, medical nutrition, and nutritional improvements for the under-nourished. The acquisition of Adare Biome will also position dsm-firmenich as a leader in the growing microbiome management market for pets and expand its animal health range, where the stability of postbiotics means they can be incorporated into premix feed solutions.
Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich is the ideal company to take Adare Biome to the next level and realise the growth potential of postbiotics. They have the infrastructure, together with strong commercialisation and science capabilities, to scale the significant scientific research that we've achieved over the years. Moreover, dsm-firmenich's purpose of bringing progress to life resonates strongly with the team."
The Global MillerJuly 3, 2023 - dsm-firmenich, innovators in nutrition, health, and beauty, confirms the completion of its acquisition of Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.
Philip Eykerman, dsm-firmenich's President Health, Nutrition & Care, said: "Adare Biome, as a global leader in the research and manufacturing of postbiotics with over a century of pioneering science in its heritage, is a perfect fit for dsm-firmenich that will complement three of our four Business Units. The Adare Biome teams bring great knowledge in this area which will greatly help in driving our 'Health from the Gut' strategy and enable us to accelerate the creation of next-generation bionics to support the health of people and animals. We are excited about the new opportunities this move will unlock, as dsm-firmenich's strong global presence and reach in local markets will enable us to deliver Adare Biome products to customers in a faster, more efficient way to bring the proven benefits of postbiotics to a wider range of people around the world. We welcome the Adare Biome team members to the dsm-firmenich family."
dsm-firmenich intends to extend the availability of Adare Biome's over the counter post biotic supplement for relieving gut upsets Lactéol® through its B2C unit, i-Health. Further development of post biotic B2B ingredients will include opportunities in dietary supplements, early life nutrition, medical nutrition, and nutritional improvements for the under-nourished. The acquisition of Adare Biome will also position dsm-firmenich as a leader in the growing microbiome management market for pets and expand its animal health range, where the stability of postbiotics means they can be incorporated into premix feed solutions.
Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich is the ideal company to take Adare Biome to the next level and realise the growth potential of postbiotics. They have the infrastructure, together with strong commercialisation and science capabilities, to scale the significant scientific research that we've achieved over the years. Moreover, dsm-firmenich's purpose of bringing progress to life resonates strongly with the team."
This blog is maintained by The Global Miller staff and is supported by the magazine Milling and Grain
which is published by Perendale Publishers Limited.
No comments:
Post a Comment